Safety of targeting tumor endothelial cell antigens

Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™

(2015) Thomas E Ichim et al.   Journal of Translational Medicine

Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC)

(2015) Petr G Lokhov et al.   Human Vaccines & Immunotherapeutics

Anti-Yo Antibody Uptake and Interaction with Its Intracellular Target Antigen Causes Purkinje Cell Death in Rat Cerebellar Slice Cultures: A Possible Mechanism for Paraneoplastic Cerebellar Degeneration in Humans with Gynecological or Breast Cancers

(2015) John E. Greenlee et al.   PLoS One

Tumor Vasculature Is Regulated by FGF/FGFR Signaling-Mediated Angiogenesis and Bone Marrow-Derived Cell Recruitment: This Mechanism Is Inhibited by SSR128129E, the First Allosteric Antagonist of FGFRs

(2014) Pierre Fons et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature

(2014) John G. Facciponte et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial

(2014) J.V. Gavilondo et al.   VACCINE

Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis

(2014) Paul Davis et al.   OncoTargets and Therapy

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

(2013) Sampurna Chatterjee et al.   JOURNAL OF CLINICAL INVESTIGATION

Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination

(2013) Charlotte Anderberg et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF

(2013) Aymara Fernández Lorente et al.   World Journal of Surgical Oncology

Tumor Endothelial Cells

(2013) A. C. Dudley   Cold Spring Harbor Perspectives in Medicine

The immunological identity of tumor

(2013) Jason Miska et al.   OncoImmunology

Mechanisms of FGFR-mediated carcinogenesis

(2012) Imran Ahmad et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma

(2012) Minoru Tanaka et al.   CANCER SCIENCE

Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents

(2012) M Jarosz et al.   GENE THERAPY

The role of antigen-specific and non-specific immunotherapy in the treatment of cancer

(2012) Arta M. Monjazeb et al.   Journal of Immunotoxicology

Whole Cell Vaccines—Past Progress and Future Strategies

(2012) Bridget P. Keenan et al.   SEMINARS IN ONCOLOGY

VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics

(2012) Amanda W. Lund et al.   Cell Reports

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer

(2010) P J Wysocki et al.   CANCER GENE THERAPY

Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer

(2010) E. Fischer et al.   JOURNAL OF IMMUNOLOGY

Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma

(2010) B K Haller et al.   ONCOGENE

Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates

(2010) Yanelys Morera et al.   VACCINE

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study

(2009) P. Quaglino et al.   ANNALS OF ONCOLOGY

Endosialin: from vascular target to biomarker for human sarcomas

(2009) Rebecca G Bagley   Biomarkers in Medicine

Characterization of TEM1/endosialinin human and murine brain tumors

(2009) Eleanor B Carson-Walter et al.   BMC CANCER

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

(2009) Motoki Miyazawa et al.   CANCER SCIENCE

VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2

(2009) Z Zhang et al.   CELL DEATH AND DIFFERENTIATION

An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model

(2009) M. M. Seavey et al.   JOURNAL OF IMMUNOLOGY

Molecular Characterization of Human Breast Tumor Vascular Cells

(2008) Rajendra Bhati et al.   AMERICAN JOURNAL OF PATHOLOGY

Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells

(2008) Sven Christian et al.   AMERICAN JOURNAL OF PATHOLOGY

Integrins

(2008) Rita Silva et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma

(2008) C. Rouleau et al.   CLINICAL CANCER RESEARCH

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy

(2008) Yurai Okaji et al.   EUROPEAN JOURNAL OF CANCER